Diabetic Med:体育活动与较低的胰岛素和C肽相关?

2019-05-07 不详 网络

近日,国际杂志 《Diabetic Med》上在线发表一项关于糖尿病家庭的儿童和青少年在葡萄糖激发期间,体育活动与较低的胰岛素和C肽相关的研究。

近日,国际杂志 《Diabetic Med》上在线发表一项关于糖尿病家庭的儿童和青少年在葡萄糖激发期间,体育活动与较低的胰岛素和C肽相关的研究。

糖尿病家族史的儿童和青少年超重风险增加,但体育活动对这些儿童潜在有益影响知之甚少。本研究的目的是研究中度至剧烈体力活动(MVPA)与患有1糖尿病或妊娠糖尿病家庭背景的儿童和青少年的代谢和炎症风险之间的关系。

使用加速度计进行的有效MVPA测量可从234名参与者(中位年龄,10.2年)获得,他们与1型或妊娠期糖尿病患者有一级亲属关系。在横断面分析中,进行人体测量和代谢测量并测量细胞因子,并与MVPA测量值相关联,逐步校正混杂因子。

在用口服葡萄糖耐量试验应激期间,MVPA与胰岛素和C肽呈负相关。MVPA也与胰岛素敏感指数显著正相关,而MVPABMI,血压或细胞因子水平之间未发现一致的显著相关性。

研究结果表明,体育活动可能对患有糖尿病家庭背景的儿童和青少年的胰岛素和C肽代谢产生有益影响,但没有证据表明与其他健康相关结果存在保护性关联。

原始出处:

K. UngethümM. JolinkM. Hippichet al. Physical activity is associated with lower insulin and Cpeptide during glucose challenge in children and adolescents with family background of diabetes

本文系梅斯医学(MedSci)原创编译整理,转载需授权!


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1639106, encodeId=00d11639106c7, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Tue Nov 26 12:49:00 CST 2019, time=2019-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1750070, encodeId=5ee71e50070dd, content=<a href='/topic/show?id=be7c8385345' target=_blank style='color:#2F92EE;'>#胰岛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83853, encryptionId=be7c8385345, topicName=胰岛)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a7a536274692, createdName=baoya, createdTime=Tue Nov 05 15:49:00 CST 2019, time=2019-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1761113, encodeId=82fd1e6111363, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Fri Jun 07 05:49:00 CST 2019, time=2019-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1970720, encodeId=d13f19e0720c6, content=<a href='/topic/show?id=fa5d5919df' target=_blank style='color:#2F92EE;'>#Diabetic#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5919, encryptionId=fa5d5919df, topicName=Diabetic)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8949377, createdName=chenzhuanggui, createdTime=Sun Sep 29 16:49:00 CST 2019, time=2019-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1416404, encodeId=e86d141640437, content=<a href='/topic/show?id=2b8056151e' target=_blank style='color:#2F92EE;'>#C肽#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5615, encryptionId=2b8056151e, topicName=C肽)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=19203173818, createdName=俅侠, createdTime=Thu May 09 11:49:00 CST 2019, time=2019-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609742, encodeId=f6921609e4231, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Thu May 09 11:49:00 CST 2019, time=2019-05-09, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1639106, encodeId=00d11639106c7, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Tue Nov 26 12:49:00 CST 2019, time=2019-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1750070, encodeId=5ee71e50070dd, content=<a href='/topic/show?id=be7c8385345' target=_blank style='color:#2F92EE;'>#胰岛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83853, encryptionId=be7c8385345, topicName=胰岛)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a7a536274692, createdName=baoya, createdTime=Tue Nov 05 15:49:00 CST 2019, time=2019-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1761113, encodeId=82fd1e6111363, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Fri Jun 07 05:49:00 CST 2019, time=2019-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1970720, encodeId=d13f19e0720c6, content=<a href='/topic/show?id=fa5d5919df' target=_blank style='color:#2F92EE;'>#Diabetic#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5919, encryptionId=fa5d5919df, topicName=Diabetic)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8949377, createdName=chenzhuanggui, createdTime=Sun Sep 29 16:49:00 CST 2019, time=2019-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1416404, encodeId=e86d141640437, content=<a href='/topic/show?id=2b8056151e' target=_blank style='color:#2F92EE;'>#C肽#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5615, encryptionId=2b8056151e, topicName=C肽)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=19203173818, createdName=俅侠, createdTime=Thu May 09 11:49:00 CST 2019, time=2019-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609742, encodeId=f6921609e4231, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Thu May 09 11:49:00 CST 2019, time=2019-05-09, status=1, ipAttribution=)]
    2019-11-05 baoya
  3. [GetPortalCommentsPageByObjectIdResponse(id=1639106, encodeId=00d11639106c7, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Tue Nov 26 12:49:00 CST 2019, time=2019-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1750070, encodeId=5ee71e50070dd, content=<a href='/topic/show?id=be7c8385345' target=_blank style='color:#2F92EE;'>#胰岛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83853, encryptionId=be7c8385345, topicName=胰岛)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a7a536274692, createdName=baoya, createdTime=Tue Nov 05 15:49:00 CST 2019, time=2019-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1761113, encodeId=82fd1e6111363, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Fri Jun 07 05:49:00 CST 2019, time=2019-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1970720, encodeId=d13f19e0720c6, content=<a href='/topic/show?id=fa5d5919df' target=_blank style='color:#2F92EE;'>#Diabetic#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5919, encryptionId=fa5d5919df, topicName=Diabetic)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8949377, createdName=chenzhuanggui, createdTime=Sun Sep 29 16:49:00 CST 2019, time=2019-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1416404, encodeId=e86d141640437, content=<a href='/topic/show?id=2b8056151e' target=_blank style='color:#2F92EE;'>#C肽#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5615, encryptionId=2b8056151e, topicName=C肽)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=19203173818, createdName=俅侠, createdTime=Thu May 09 11:49:00 CST 2019, time=2019-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609742, encodeId=f6921609e4231, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Thu May 09 11:49:00 CST 2019, time=2019-05-09, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1639106, encodeId=00d11639106c7, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Tue Nov 26 12:49:00 CST 2019, time=2019-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1750070, encodeId=5ee71e50070dd, content=<a href='/topic/show?id=be7c8385345' target=_blank style='color:#2F92EE;'>#胰岛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83853, encryptionId=be7c8385345, topicName=胰岛)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a7a536274692, createdName=baoya, createdTime=Tue Nov 05 15:49:00 CST 2019, time=2019-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1761113, encodeId=82fd1e6111363, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Fri Jun 07 05:49:00 CST 2019, time=2019-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1970720, encodeId=d13f19e0720c6, content=<a href='/topic/show?id=fa5d5919df' target=_blank style='color:#2F92EE;'>#Diabetic#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5919, encryptionId=fa5d5919df, topicName=Diabetic)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8949377, createdName=chenzhuanggui, createdTime=Sun Sep 29 16:49:00 CST 2019, time=2019-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1416404, encodeId=e86d141640437, content=<a href='/topic/show?id=2b8056151e' target=_blank style='color:#2F92EE;'>#C肽#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5615, encryptionId=2b8056151e, topicName=C肽)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=19203173818, createdName=俅侠, createdTime=Thu May 09 11:49:00 CST 2019, time=2019-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609742, encodeId=f6921609e4231, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Thu May 09 11:49:00 CST 2019, time=2019-05-09, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1639106, encodeId=00d11639106c7, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Tue Nov 26 12:49:00 CST 2019, time=2019-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1750070, encodeId=5ee71e50070dd, content=<a href='/topic/show?id=be7c8385345' target=_blank style='color:#2F92EE;'>#胰岛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83853, encryptionId=be7c8385345, topicName=胰岛)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a7a536274692, createdName=baoya, createdTime=Tue Nov 05 15:49:00 CST 2019, time=2019-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1761113, encodeId=82fd1e6111363, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Fri Jun 07 05:49:00 CST 2019, time=2019-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1970720, encodeId=d13f19e0720c6, content=<a href='/topic/show?id=fa5d5919df' target=_blank style='color:#2F92EE;'>#Diabetic#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5919, encryptionId=fa5d5919df, topicName=Diabetic)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8949377, createdName=chenzhuanggui, createdTime=Sun Sep 29 16:49:00 CST 2019, time=2019-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1416404, encodeId=e86d141640437, content=<a href='/topic/show?id=2b8056151e' target=_blank style='color:#2F92EE;'>#C肽#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5615, encryptionId=2b8056151e, topicName=C肽)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=19203173818, createdName=俅侠, createdTime=Thu May 09 11:49:00 CST 2019, time=2019-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609742, encodeId=f6921609e4231, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Thu May 09 11:49:00 CST 2019, time=2019-05-09, status=1, ipAttribution=)]
    2019-05-09 俅侠
  6. [GetPortalCommentsPageByObjectIdResponse(id=1639106, encodeId=00d11639106c7, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Tue Nov 26 12:49:00 CST 2019, time=2019-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1750070, encodeId=5ee71e50070dd, content=<a href='/topic/show?id=be7c8385345' target=_blank style='color:#2F92EE;'>#胰岛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83853, encryptionId=be7c8385345, topicName=胰岛)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a7a536274692, createdName=baoya, createdTime=Tue Nov 05 15:49:00 CST 2019, time=2019-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1761113, encodeId=82fd1e6111363, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Fri Jun 07 05:49:00 CST 2019, time=2019-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1970720, encodeId=d13f19e0720c6, content=<a href='/topic/show?id=fa5d5919df' target=_blank style='color:#2F92EE;'>#Diabetic#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5919, encryptionId=fa5d5919df, topicName=Diabetic)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8949377, createdName=chenzhuanggui, createdTime=Sun Sep 29 16:49:00 CST 2019, time=2019-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1416404, encodeId=e86d141640437, content=<a href='/topic/show?id=2b8056151e' target=_blank style='color:#2F92EE;'>#C肽#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5615, encryptionId=2b8056151e, topicName=C肽)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=19203173818, createdName=俅侠, createdTime=Thu May 09 11:49:00 CST 2019, time=2019-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609742, encodeId=f6921609e4231, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Thu May 09 11:49:00 CST 2019, time=2019-05-09, status=1, ipAttribution=)]

相关资讯

糖尿病人怎么吃?ADA官方饮食“泌”籍来了!

2019年5月刊的Diabetes Care上发表了一系列关于糖尿病营养治疗的文章,包括脱胎于2014年《成年糖尿病患者治疗推荐》的新共识声明、相关述评以及营养治疗相关的四项研究。共识声明的第一作者、来自美国西雅图华盛顿大学的Alison B. Evert指出:“糖尿病和糖尿病前期已经波及了全世界大部分人群,各类人群的文化背景、个人生活习惯、合并症以及社会经济环境均有所不同,那种为了简化信息传

Cancer:糖尿病不良控制能够增加去势抵抗性前列腺癌和转移的风险

尽管糖尿病与前列腺癌(PC)风险呈现负相关关系,但是血糖控制对PC进展的的影响仍旧未知。最近,有研究人员在经历根治性前列腺切除(RP)男性糖尿病患者中,探究了血红蛋白A1c(HbA1c)和长期PC结果之间的相关性。研究共有1409名男性,其中699名患者(50%)HbA1c值<6.5%,631名(45%)患者的HbA1c值为6.5%到7.9%之间,79名(6%)患者的HbA1c值不小于8%。

DIABETOLOGIA:前列腺素E2/EP2受体信号通路在糖尿病大鼠模型中促进糖尿病视网膜病变

糖尿病视网膜病变是由炎症和凋亡相关的视网膜内皮细胞损伤引起的糖尿病常见的微血管并发症。前列腺素E2 (PGE2)是这些生物过程的关键调控因子。本研究假设调节PGE2及其E-prostanoid受体(EP2R)可以预防糖尿病mellitus引起的炎症和微血管功能障碍。

DIABETOLOGIA:新型寡核苷酸药物VE-cadherin可治疗糖尿病眼并发症的视网膜病变

糖尿病视网膜病变的一个主要特征是视网膜血屏障的破坏,并导致黄斑水肿。我们开发了一种新型寡核苷酸药物CD5-2,它能特异性地增加内皮细胞屏障完整性关键连接蛋白的表达,即血管内皮特异性cadherin (VE-cadherin)。CD5-2可以阻止促血管生成的microRNA miR-27a沉默mRNA。本研究对CD5-2在动物眼部新生血管形成和血管渗漏模型中进行了评估,以确定其对糖尿病视网膜病变的潜

Brit J Cancer:糖尿病前期和糖尿病与胃腺癌风险有关

由此可见,该研究结果并不支持糖尿病前期或糖尿病会增加胃腺癌风险的假设。

Diabetic Med:为妊娠设计的静脉胰岛素方案可降低妊娠期糖尿病妇女服用倍他米松后新生儿低血糖

妊娠期糖尿病(GDM)妇女使用倍他米松后,常见明显的高血糖,并可能导致新生儿低血糖。近日,国际杂志 《Diabetic Med》上在线发表关于一项为妊娠设计的静脉胰岛素方案可降低妊娠期糖尿病妇女服用倍他米松后新生儿低血糖的研究。